Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey
Articles by Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey
Andrew M. Evens, DO, MSc, discusses the design of a retrospective analysis evaluating in relapsed/refractory classic Hodgkin lymphoma.
Andrew M. Evens, DO, MSc, discusses highlights from the 2021 RWJ Annual Clinical and Practice Research Summit.
Novel Therapies for R/R Follicular Lymphoma
ByIan Flinn, MD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute A panel of hematologists/oncologists remark on the transformations occurring in relapsed/refractory follicular lymphoma as newer, novel therapies continue to emerge.
CAR T for R/R FL: Treatment Considerations
ByIan Flinn, MD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute Factors that should be considered when evaluating patients with relapsed/refractory follicular lymphoma for CAR T-cell therapy.
CAR T-Cell Therapy for R/R Follicular Lymphoma
ByIan Flinn, MD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute Implications for adding CAR T-cell therapy to the treatment armamentarium for relapsed/refractory follicular lymphoma in the near future.
ZUMA-5 in R/R Follicular Lymphoma
ByIan Flinn, MD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute Caron A. Jacobson, MD, MMSc, of Dana-Farber Cancer Institute, comments on current data demonstrated by the ZUMA-5 trial in relapsed/refractory follicular lymphoma and the potential use of CAR T-cell therapy moving forward.
Treating Follicular Lymphoma With Early Progression
ByIan Flinn, MD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute Approaches to sequencing therapy for patients with follicular lymphoma who experience progression of disease within 24 months (POD24).
Emerging Therapies for R/R Follicular Lymphoma
ByIan Flinn, MD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute An overview of novel therapies under investigation for the treatment of relapsed/refractory follicular lymphoma and special considerations regarding treating patients with newer, novel agents in the community setting.
Case Discussion: 68-Year-Old With R/R Follicular Lymphoma
ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute A panel of hematologist-oncologists share best practices for managing a 68-year-old male with relapsed/refractory follicular lymphoma who is under consideration for treatment with tazemetostat.
R/R Follicular Lymphoma: Testing for EZH2
ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute Andrew M. Evens, DO, MSc, FACP, of Rutgers Cancer Institute of New Jersey, comments on the rationale for testing for EZH2 mutations in relapsed/refractory follicular lymphoma.
EZH2 Inhibition in R/R FL: Safety & Efficacy Data
ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute Takeaways of safety and efficacy data published on tazemetostat, an EZH2 inhibitor, to treat relapsed/refractory follicular lymphoma, and implications for using the drug in clinical practice.
Tazemetostat for R/R Follicular Lymphoma
ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute Drs Andrew M. Evens and Loretta J. Nastoupil remark on the recent approval of tazemetostat, an EZH2 inhibitor, as treatment for relapsed/refractory follicular lymphoma and highlight which types of patients are most appropriate to manage with this drug.
R2 Regimen for R/R Follicular Lymphoma
ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute An overview of the MAGNIFY data and implications for treating appropriate patients with relapsed/refractory follicular lymphoma with the R2 regimen.
PI3K Inhibitors for R/R Follicular Lymphoma
ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute Recommendations for treating patients with relapsed/refractory follicular lymphoma with an available PI3K inhibitor and managing adverse events from treatment.
R/R Follicular Lymphoma: Third-Line Treatment Options
ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute Currently available third-line treatment options for relapsed/refractory follicular lymphoma and unique considerations when selecting an appropriate therapy in this setting.
Transplantation for R/R Follicular Lymphoma
ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute The rationale for treating patients with relapsed/refractory follicular lymphoma with allogeneic or autologous transplantation in the current era of novel therapies.
MRD Testing in R/R Follicular Lymphoma
ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute Drs Caron A. Jacobson and Krish Patel comment on NGS (next-generation sequencing) and MRD (minimal residual disease) testing in relapsed/refractory follicular lymphoma.
Role of Rebiopsy in R/R Follicular Lymphoma
ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute The rationale for rebiopsying patients who have relapsed/refractory follicular lymphoma and the types of molecular information that can be applied to treatment decisions.
R/R Follicular Lymphoma: Second-line Treatment Selection
ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute Factors that hematologist-oncologists need to consider when selecting second-line therapy for relapsed follicular lymphoma.
R/R Follicular Lymphoma: Patient Prognosis
ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute Insight regarding the prognosis for patients with follicular lymphoma who relapse and impact of treatment sequencing on this trajectory.
CAR T for R/R FL: Treatment Considerations
Novel Therapies for R/R Follicular Lymphoma
Treating Follicular Lymphoma With Early Progression
Dr. Evens on the Design of a Retrospective Analysis Evaluating Salvage Regimens in R/R Hodgkin Lymphoma
Emerging Therapies for R/R Follicular Lymphoma
R2 Regimen for R/R Follicular Lymphoma